Cubicin Advertising Claims Pose Public Health Risk – FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Misleading claims are a "significant public health risk" that "could lead to therapeutic failure and death," FDA says. Cubist removed taglines deemed violative by the agency from its website shortly after receiving the letter. Cubicin promotion has previously been cited by FDA.